Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1612 1639 1675 1684
This examiner grants 29% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 17911509 | SINGLE-CELL COMBINATORIAL INDEXED CYTOMETRY SEQUENCING | Non-Final OA | The Regents of the University of California |
| 17750844 | AFFINITY PURIFICATION SEQUENCING | Non-Final OA | The Regents of the University of California |
| 16735628 | SOLID-PHASE POLYMER SYNTHESIS ON REUSABLE SUBSTRATES | Final Rejection | MICROSOFT TECHNOLOGY LICENSING, LLC |
| 16936197 | FUNCTIONALIZED SOLID SUPPORT | Non-Final OA | Massachusetts Institute of Technology |
| 18297137 | METHODS AND COMPOSITIONS FOR ANALYZING ANTIGEN BINDING MOLECULES | Non-Final OA | 10x Genomics, Inc. |
| 17843758 | METHODS TO GENERATE CIRCULARIZABLE PROBES IN SITU | Non-Final OA | 10x Genomics, Inc. |
| 17476395 | SYSTEMS AND METHODS FOR BARCODE DESIGN AND DECODING | Non-Final OA | 10x Genomics, Inc. |
| 16625100 | HIGH-THROUGHPUT SINGLE-CELL TRANSCRIPTOME LIBRARIES AND METHODS OF MAKING AND OF USING | Non-Final OA | University of Washington |
| 17782805 | CELL PREPARATION WITH A SERIES OF DETECTION DEVICES | Non-Final OA | Hewlett-Packard Development Company, L.P. |
| 17165293 | Affinity Reagent and Catalyst Discovery Through Fiber-Optic Array Scanning Technology | Final Rejection | SRI International |
| 18033002 | COMPOSITIONS FOR AND METHODS OF CO-ANALYZING CHROMATIN STRUCTURE AND FUNCTION ALONG WITH TRANSCRIPTION OUTPUT | Non-Final OA | Duke University |
| 17178210 | PRECISION DRUG SCREENING FOR PERSONALIZED CANCER THERAPY | Final Rejection | Duke University |
| 17928690 | METHODS AND COMPOSITIONS FOR IN VITRO AFFINITY MATURATION OF MONOCLONAL ANTIBODIES | Non-Final OA | University of Southern California |
| 18074790 | SINGLE CELL WHOLE GENOME LIBRARIES AND COMBINATORIAL INDEXING METHODS OF MAKING THEREOF | Final Rejection | Oregon Health & Science University |
| 17938254 | Polynucleotide Barcodes for Multiplexed Proteomics | Non-Final OA | Singular Genomics Systems, Inc. |
| 17913189 | IMMUNOTHERAPEUTIC TARGETS IN MULTIPLE MYELOMA AND METHODS FOR THEIR IDENTIFICATION | Non-Final OA | THE TRUSTEES OF INDIANA UNIVERSITY |
| 18195763 | METHODS FOR NON-INVASIVE ASSESSMENT OF FETAL GENETIC VARIATIONS THAT FACTOR EXPERIMENTAL CONDITIONS | Non-Final OA | Sequenom, Inc. |
| 18305932 | COMPARTMENTALISED COMBINATORIAL CHEMISTRY BY MICROFLUIDIC CONTROL | Non-Final OA | UNITED KINGDOM RESEARCH AND INNOVATION |
| 17922685 | COMPOSITIONS AND METHODS FOR IDENTIFYING NANOBODIES AND NANOBODY AFFINITIES | Non-Final OA | UNIVERSITY OF PITTSBURGH-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION |
| 18021456 | FUNCTIONAL SCREENING USING DROPLET-BASED MICROFLUIDICS | Non-Final OA | Nankai University |
| 17919481 | Immune Cell Redirecting Compositions and Therapeutic Uses Thereof | Final Rejection | Children's Healthcare of Atlanta, Inc. |
| 18052337 | MODULAR NUCLEIC ACID ADAPTERS | Final Rejection | Roche Sequencing Solutions, Inc. |
| 18250423 | METHODS AND KITS FOR ENRICHING FOR POLYNUCLEOTIDES | Non-Final OA | Eclipse Bioinnovations, Inc. |
| 18296375 | RNA PROBE FOR MUTATION PROFILING AND USE THEREOF | Non-Final OA | xFOREST THERAPEUTICS CO., LTD. |
| 16919947 | BIOMARKERS AND METHODS FOR PREDICTING PREECLAMPSIA | Final Rejection | Sera Prognostics, Inc. |
| 16982349 | METHOD AND SYSTEM FOR FABRICATING DNA SEQUENCING ARRAYS | Final Rejection | CENTRILLION TECHNOLOGY HOLDINGS CORPORATION |
| 15563015 | METHODS FOR PERFORMING SPATIAL PROFILING OF BIOLOGICAL MOLECULES | Final Rejection | CENTRILLION TECHNOLOGY HOLDINGS CORPORATION |
| 17881962 | NONINVASIVE DETECTION OF FETAL ANEUPLOIDY IN EGG DONOR PREGNANCIES | Final Rejection | Ariosa Diagnostics, Inc. |
| 17739029 | METHODS FOR STUDYING OR IDENTIFYING A BIOLOGICALLY ACTIVE AGENT USING SAPOSIN LIPOPROTEIN PARTICLE STRUCTURES | Non-Final OA | Salipro Biotech AB |
| 17602254 | METHODS AND SYSTEMS FOR SCREENING USING MICROCAPILLARY ARRAYS | Final Rejection | xCella Biosciences, Inc. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy